Adipocytokine levels and their association with clinical and laboratory parameters in women aged 25–44 years with different metabolic phenotypes

• Svetlana V. Mustafina
• Vlada I. Alferova
• Oksana D. Rymar
• Liliya V. Shcherbakova
• Diana V. Denisova
• Elena V. Kashtanova
• Darya A. Vinter
• Yulia I. Ragino

Abstract

Purpose: to study the levels of leptin, adiponectin, adipsin, tumor necrosis factor α (TNF-α), interleukin 6 (IL‑6) and their association with some clinical, laboratory, hormonal parameters in women aged 25–44 years.

Material and methods. The study based on a representative sample of an unorganized population of women aged 25–44 years, 655 women were included in the analysis. In accordance with the protocol of the study, anthropometric, biochemical, and hormonal examinations were carried out. Statistical analysis was performed using the SPSS‑13 package.

Results. According to the epidemiological study, women with metabolically unhealthy phenotype (MUHP) had a significantly higher median leptin than in the group with metabolically healthy phenotype (MHP) [13.8 (6.8; 19.4) and 5.6 (2.6; 8.8) ng/mL], IL‑6 [1.6 (0.8; 4.2) and 0.9 (0.4; 1.6) pg/mL], and TNF-α [4.9 (3.1; 7.9); 3.9 (2.6; 6.5) pg/ml]. The largest number of correlations with cardiometabolic risk factors were found for leptin, TNF-α and IL‑6. Adiponectin and adipsin are little associated with metabolic parameters and the medians of these adipocytokines did not differ in MUHP and MHP groups. In the course of the ROC (Receiver Operating Characteristic) analysis, we found that in a sample of women aged 25–44 years, the level of leptin capable of recognizing MUHP was 8.6 ng/ml (Area Under Curve, AUC=0.77), IL‑6 – 1.57 pg/ml (AUC=0.67). According to multivariate logistic regression analysis, in women 25–44 years old, the chance of having MUHP increases with an increase in age by a year by 1%, alkaline phosphatase by 1 U/l by 1%, with an increase in leptin by 1 ng/ml by 7%, C-peptide by 1 ng/ml by 2.4 times.

Conclusion. 1. Women aged 25–44 years with MUHP have significantly higher median leptin, IL‑6 and TNF-α than those with MHP, and it increases with increasing BMI in both MHP and MUHP. 2. The largest number of correlations with cardiometabolic risk factors was found for leptin, TNF-α and IL‑6. 3. According to ROC analysis, leptin levels ≥8.6 ng/mL and IL‑6 ≥1.57 pg/mL are associated with a high risk of MUHP.

Keywords:metabolically healthy phenotype; leptin; adipsin; tumor necrosis factor α; interleukin 6; adiponectin

References

1. Romantsova T.I., Ostrovskaya E.V. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2015; 13 (21): 75–87. (in Russian)

2. Biondi G., Marrano N., Borrelli A., et al. Adipose tissue secretion pattern influences β-cell wellness in the transition from obesity to type 2 diabetes. Int J Mol Sci. 2022; 23 (10): 5522. DOI: https://doi.org/10.3390/ijms23105522

3. Phillips C.M. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann N Y Acad Sci. 2017; 1391 (1): 85–100. DOI: https://doi.org/10.1111/nyas.13230

4. Stefan N., Schick F., Haring H.U. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017; 26: 292–300. DOI: https://doi.org/10.1016/j.cmet.2017.07.008

5. Phillips C.M., Perry I.J. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013; 98 (10): E 1610–9. DOI: https://doi.org/10.1210/jc.2013-2038

6. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014; 85: 49–61. DOI: https://doi.org/10.1038/ki.2013.444

7. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. URL: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf

8. Hivert M.F., Sullivan L.M., Fox C.S., et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab. 2008; 93 (8): 3165–72. DOI: https://doi.org/10.1210/jc.2008-0425

9. Motie M., Evangelista L.S., Horwich T., et al. Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Exp Ther Med. 2014; 8 (1): 181–6. DOI: https://doi.org/10.3892/etm.2014.1673

10. Gómez-Ambrosi J., Catalán V., Rodríguez A., et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014; 37 (10): 2813–21. DOI: https://doi.org/10.2337/dc14-0937

11. Boyarinova M.A., Orlov A.V., Rotar’ O.P., et al. Adipokines level in metabolically healthy obese Saint-Petersburg Inhabitants (ESSE-RF). Kardiologiya [Cardiology]. 2016; 56 (8): 40–5. DOI: https://doi.org/10.18565/cardio.2016.8.40-45 (in Russian)

12. Verbovoy A.F., Verbovaya N.I., Dolgikh Y.A. Obesity is the basis of metabolic syndrome. Ozhirenie i metabolism [Obesity and Metabolism]. 2021; 18 (2): 142–9. DOI: https://doi.org/10.14341/omet12707 (in Russian)

13. Alferova V.I., Mustafina S.V. The role of adipokines in the development of cardiometabolic disorders in humans. Ateroskleroz [Atherosclerosis]. 2022; 18 (4): 388–94. DOI: https://doi.org/10.52727/2078-256X-2022-18-4-388-394 (in Russian)

14. Borodkina D.A., Gruzdeva O.V., Akbasheva O.E., et al. Leptin resistance: unsolved diagnostic issues. Problemy endokrinnoy patologii [Problems of Endocrine Pathology]. 2018; 64 (1): 62–6. DOI: https://doi.org/10.14341/probl8740 (in Russian)

15. Hwang S.Y., Seon M.J., Lee J.H., Kim O.Y. Relationship between adipose tissue derived hormones and cardiometabolic risk according to obesity status. Clin Nutr Res. 2021; 10 (3): 206–18. DOI: https://doi.org/10.7762/cnr.2021.10.3.206

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)